je.st
news
PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)
2014-06-04 13:02:23| drugdiscoveryonline News Articles
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older
Tags: positive
opinion
receives
therapeutics
Category:Biotechnology and Pharmaceuticals